Systemic inflammatory response syndrome in a patient diagnosed with high grade inflammatory triple negative breast cancer: a case report of a potentially rare paraneoplastic syndrome by Boshier, PRB et al.
Boshier et al. Exp Hematol Oncol  (2016) 5:16 
DOI 10.1186/s40164-016-0045-2
CASE REPORT
Systemic inflammatory response 
syndrome in a patient diagnosed with high 
grade inflammatory triple negative breast 
cancer: a case report of a potentially rare 
paraneoplastic syndrome
Piers R. Boshier1, Rosie Sayers2, Dimitri J. Hadjiminas2, Charles Mackworth‑Young3, Susan Cleator4 
and Daniel R. Leff1*
Abstract 
Background: Inflammatory breast cancer is a complex pathological entity associated with poor outcomes. This loco‑
regional disease is characterised by a rapid clinical course in the presence breast erythema and infiltration of dermal 
lymphatics by tumours cells. Herein we describe a case of inflammatory breast cancer with a rare presentation and 
disease course defined by a profound systemic inflammatory response in the absence of an infective cause.
Case presentation: The patient presented with pyrexia and malaise following a recent tissue diagnosis of inflamma‑
tory breast cancer. At the time of admission the patient demonstrated clinical features of the systemic inflammatory 
response syndrome (SIRS) in the presence of a negative septic screen. Her condition deteriorated despite systemic 
broad spectrum intravenous antibiotics and she underwent surgical debulking of a 180 × 135 × 100 mm (821 g) 
primary tumour composed of oedematous, friable and haemorrhagic tissue (pT4,N1a,M0; oestrogen/progesterone/
HER‑2 receptor negative). Following surgery, the clinical picture dramatically improved with cessation of SIRS and 
normalisation of inflammatory markers. After 4 weeks the patient required readmission to hospital due to recurrent 
SIRS and negative septic screen. The patient received treatment with systemic chemotherapy showing transient clini‑
cal improvement and suppression of SIRS. Despite on going chemotherapy, systemic antibiotics and a trial of steroid 
therapy the patient died 5 months after her initial presentation to hospital. At the time of death she demonstrated 
persistent SIRS with elevated inflammatory markers.
Conclusion: This is the first case report of inflammatory breath cancer associated with SIRS in the absence of clini‑
cally confirmed infection. Important learning points highlighted by this case are: (a) recognition of the diagnostic and 
therapeutic uncertainties that still exist in the context of inflammatory breast cancer; (b) appreciation of the potential 
paraneoplastic systemic inflammatory manifestations of this disease, and finally; (c) the importance a multidisciplinary 
and multimodal approach to treatment.
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Background
Inflammatory breast cancer (IBC) is a complex clinico-
pathological entity that is associated with a poor prog-
nosis [1]. Consensus guidelines for the diagnosis of IBC 
describe a locoregional disease characterised by rapid 
onset breast erythema, oedema and/or peau d’orange 
with or without an underlying palpable mass [1]. Whilst 
localised skin warmth may be present, a systemic inflam-
matory response is not a recognised feature of this dis-
ease and if present is likely to suggest an alternative 
diagnosis.
The systemic inflammatory response syndrome (SIRS) 
is a multifaceted pathophysiological response to a range 
of noxious stimuli, whose characteristics were first 
defined in 1992 [2]. The link between inflammation and 
cancer has long been established [3] and is associated 
with readily detectable clinical and biochemical changes 
[4]. The mechanism by which cancer induces both local 
and systemic inflammatory responses is yet to be fully 
elucidated, although it is thought to involve complex 
interactions between cancerous cells and adjacent stroma 
leading to tissue damage and initiation of an acute phase 
response [3].
Traditionally the ‘inflammatory’ response observed in 
IBC is attributed to the infiltration of dermal lymphat-
ics by tumour cells, which in turn causes congestion. 
A potent inflammatory milieu has nevertheless been 
observed in the context of IBC [5, 6]. Furthermore, raised 
serum inflammatory markers are recognised in the serum 
of up to one-third of patients with grade I-III breast can-
cer [7]. The underlying mechanism clinical significance of 
SIRS in the context of a cancer diagnosis is however yet 
to be determined.
Herein, we present an unusual case of inflammatory 
breast cancer associated with a systemic inflammatory 
response in the absence of clinical evidence of infection.
Case presentation
A 48 year old pre-menopausal Jamaican female, recently 
diagnosed with IBC affecting the left breast, was admit-
ted with a 5 day history of pyrexia and general malaise. 
Her co-morbidities included hypertension and sarcoido-
sis treated with antihypertensives and low dose oral pred-
nisolone respectively. There was no relevant family or 
travel history and no history of recent illness.
An ultrasound scan performed at the time of diagnosis, 
6 weeks prior to admission, showed a 41 mm ill-defined 
mass in the upper outer quadrant of the left breast with 
bilateral axillary nodal enlargement. Computed tomog-
raphy (CT) imaging at the time of diagnosis revealed no 
evidence of solid organ metastasis within the chest, abdo-
men or pelvis. Core biopsy of the lesion confirmed a ple-
omorphic, poorly differentiated triple negative (estrogen/
progesterone/human epidermal growth factor (HER2) 
receptor) grade III invasive ductal carcinoma.
At the time of admission, clinical examination revealed 
a large (~5  ×  10  cm) left upper outer quadrant breast 
mass with associated erythema and induration of the sur-
rounding tissue and palpable lymphadenopathy of within 
the axilla. The diagnostic criteria for systemic inflam-
matory response syndrome (SIRS) were fulfilled [heart 
rate 120; respiratory rate 26; temperature 38.7  °C; white 
blood cell count 16.9 × 109/L (neutrophils 14.9 × 109/L)] 
[2]. Biochemical markers of acute inflammation were 
observed to be markedly deranged (C-reactive pro-
tein (CRP) 385  mg/L; erythrocyte sedimentation rate 
>100 mm/h; ferritin 1044 μg/L; transferrin 0.6 g/L; albu-
min 16  g/L). Blood cultures at the time of admission, 
before initiation of antibiotic therapy, demonstrated no 
bacterial growth. Likewise an ultrasound guided aspirate 
of tissue fluid contained within the mass yielded no evi-
dence of bacterial infection.
Despite treatment with antibiotics (Cefuroxime and 
Metronidazole), 48  h after admission worsening SIRS 
was observed (heart rate 114; respiratory rate 24; Tem-
perature 39.0  °C; White blood cell count 20.0  ×  109). 
A CT scan 72  h after admission demonstrated an 
increase in size of the primary breast lesion (75 × 94 vs. 
38 × 80 mm), features in keeping with pectoralis major 
muscle invasion and associated ipsilateral lymphadenop-
athy and cervical chain adenopathy. A left upper lobe 
pulmonary nodule (9  mm) and para-aortic lymph node 
(8 mm) suspicious of metastatic spread were also noted 
in addition to small bilateral pleural and pericardial effu-
sions. Subsequent transthoracic echocardiogram and CT 
head revealed no additional abnormalities or likely source 
of infection. Serum virology and autoimmune screens 
were negative as were repeat blood and urine cultures.
Over the subsequent week she experienced contin-
ued clinical deterioration with anaemia (haemoglobin; 
87–65  g/L) and coagulopathy (fibrinogen 5.65  g/L; pro-
thrombin time 17.2  s; activate partial thromboplastin 
time 40.6 s) that required transfusion of packed red cells 
(6 units) and fresh frozen plasma (3 units). There was no 
evidence of active bleeding and haemoglobin electropho-
resis was normal. A blood film showed signs of anaemia 
with significant red cell hypochromia, anisopoikilocyto-
sis, hypersegmentated neutrophils and thrombocytosis 
with platelet clumping.
The patients condition deteriorated over the course of 
9 days with no evidence of a response to broad spectrum 
antibiotic therapy (including: Vancomycin; Ciprofloxacin; 
Tazocin, and; Meropenem) (Fig. 1) and persistently wors-
ening SIRS and episodic hypotension without objective 
evidence of an infective source. Formal nutritional assess-
ment revealed good nutritional intake and no specific 
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deficiency. Consequently the multidisciplinary team 
advised emergency excision of the left breast tumour 
mass on the assumption that the SIRS might represent a 
response to necrotic inflammatory cancer. At the time of 
surgery a 180 × 135 × 100 mm (821 g) diffusely oedema-
tous, friable and haemorrhagic tissue mass was excised 
(Fig. 2). A delayed primary closure of the wound was per-
formed on the seventh postoperative day with Yates drain 
left in situ. Histology of the resected specimen confirmed 
grade III pleomorphic carcinoma (>100 mm) with adja-
cent high grade ductal carcinoma in situ, lymphovascular 
invasion and extracapsular spread and significant necro-
sis (pT4,N1a,Mx; oestrogen/progesterone/HER-2 recep-
tor negative, E-cadherin/cytokeratin-7/p53/p63 positive) 
(Fig. 2). Radial margins were clear (>2 mm) but the deep 
resection margin was involved.
Following surgery the patient’s clinical picture dramati-
cally improved with a cessation of SIRS and normalisa-
tion of inflammatory markers. At the time of hospital 
discharge on (postoperative day 8), the patient was clini-
cally well. A multidisciplinary team decision for the con-
tinuation of therapy as an outpatient had been agreed. 
Approximately 4 weeks later she represented with recur-
rent SIRS and a left breast seroma which was formally 
drained (1.5L haemoserous fluid) and which was nega-
tive on culture. Critically, no infective source could be 
identified (blood, urine, seroma aspirate culture were 
negative). Positron emission tomography–CT performed 
soon after readmission demonstrated a recurrent mass 
(32 × 77 mm) at the site of the original tumour. In addi-
tion there was progressive bilateral lymphadenopathy 
including mediastinal nodes and bilateral intrapulmo-
nary masses with the largest present in the superior seg-
ment of the lingual measuring (22 × 40 mm). There was 
heterogeneity of the hepatic fludeoxyglucose uptake with 
increase skeletal activity, indicative of metastatic disease. 
Chemotherapy (FEC regimen; fluorouracil, epirubicin 
and cyclophosphamide) was started 6  weeks after her 
initial emergency presentation. The first cycle of chem-
otherapy was well tolerated and associated with resolu-
tion of SIRS and improvement in inflammatory markers. 
Whilst receiving the second cycle of chemotherapy as an 
outpatient, she developed neutropenia and pyrexias (cul-
ture negative) for which she received a further course of 
broad spectrum antibiotics and epidermal growth factor.
She received a third cycle of FEC chemotherapy follow-
ing which a repeat CT scan showed an increase in size of 
the primary tumour, multiple pulmonary metastasis with 
extensive nodal disease.
A subsequent aspiration of the breast cavity grew 
staphylococcus aureus, pseudomonas and enterococcus 
for which she was prescribed Linezolid and Meropenem 
but without a clinical response.
The Oncology team discussed whether second line tax-
ane chemotherapy was appropriate, but this was withheld 
because the patient’s condition deteriorated rapidly. The 
albumin at this point was 13 g/L.
Despite no impedance to the investigation, diagnosis 
and management of this patient during her care she died 
5  months after her initial presentation to hospital. At 
the time of death she demonstrated persistent SIRS with 
elevated markers of inflammation (white blood cell count 
47.6 × 109/L (Neutrophils 44.5 × 109/L); CRP 332 mg/L).
Discussion
This is the first case report of IBC associated with SIRS 
in the absence of clinically defined infection in the Eng-
lish medical literature. Important learning points high-
lighted by this case are as follows: (a) recognition of the 
diagnostic and therapeutic uncertainties that still exist in 
the context of IBC; (b) appreciation of the potential para-
neoplastic systemic inflammatory manifestations of this 
disease, and; (c) the importance a multidisciplinary and 
multimodal approach to treatment.
One feature of this case that is particularly remark-
able was the magnitude of the observed systemic inflam-
matory response. A systematic review of the literature 
revealed no previously published report of an equivalent 
systematic inflammatory response to IBC. Several case 
reports have described: fever [8]; elevated erythrocyte 
sedimentation rate [9]; elevated CRP, and; raised white 
blood cell count and in the presence of a negative septic 
Fig. 1 C‑reactive protein CRP and white blood cell WBC trends from 
time of acute admission to hospital
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screen as well as pure red cell aplasia [10] in patients 
diagnosed with IBC. Molecular profiling has sought to 
provide further insight into the pathogenesis of IBC [5]. 
Studies have found evidence for the up-regulation of 
several genes associated with inflammatory signalling 
pathways in IBC cells compared to non-IBC cells. Biѐche 
et  al., reported up regulation of interleukin (IL) 6 and 
genes encoding the CCL3/MIP1A and CCL5/RANTES 
[5]. Likewise NF-κB, cyclooxygenase family of enzymes 
and JAK/STAT signalling, all responsible for a range of 
effects including propagation of the inflammatory and 
immune response, are constitutively active in IBC [6]. Of 
note, the genetic expression of other important inflam-
matory mediators, tumour necrosis factor alpha (TNFα), 
Interferon, IL-1, IL-8 and IL-10 was similar in IBC and 
non-IBC cells [5]. Significantly increased inflammatory 
cytokine (TNFα, IL-8, IL-10 and CCL2/MCP-1) secretion 
was however observed in CD14+ monocytes isolated 
Fig. 2 Macro‑ and microscopic tumour appearance. a Macroscopic image of excised breath tissue with section through tumour (white arrow). 
Microscopic images demonstrating: b tumour cells and lymphovascular invasion of the superficial epidermis; c high magnification image of tumour 
cells, and; d tumour involvement of the deep excision margin (black arrow)
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from IBC compared to non-IBC patients [11]. Finally, 
the acute phase protein CRP has been correlated to a 
more aggressive disease phonotype and poorer progno-
sis in breast cancers patients [12]. Sphingosine-1-phos-
phate, a potent inflammatory mediator, has recently been 
reported to up-regulate the expression of CRP in breast 
cells [13]. Whilst these findings support the premise of 
an inflammatory basis for IBC their wider implications 
for a systemic inflammatory response are yet to be fully 
elucidated.
The patient fulfilled all of the clinical criteria for the 
diagnosis of SIRS as defined by the American College of 
Chest Physicians/Society of Critical Care Medicine [2]. 
An additional feature of this case was observed derange-
ment of red blood cell count and clotting function that 
required treatment with blood products. The Third Inter-
national Consensus Definitions for Sepsis and Septic 
Shock defines sepsis as a “life-threatening organ dysfunc-
tion caused by a dysregulated host response to infection” 
[14]. Critically after extensive and repeated investigation 
at the time of presentation and during the initial period 
of treatment no evidence was found for an infective ori-
gin for this response. Whilst positive bacterial cultures 
were eventually grown from the surgical wound cavity, 
isolated organisms are reported amongst the most com-
mon causes of hospital acquired wound infection [15, 
16]. As such the eventual presence of these bacteria in 
the wound is most in keeping with nosocomial infection. 
Numerous factors, including previous surgery, chemo-
therapy and general cachexia would strongly predispose 
this patient to such infection.
The unusual clinical course exhibited by this patient 
proved challenging both in terms of establishing an 
underlying mechanism and determination of appropriate 
management. Existing criteria for a diagnosis of neoplas-
tic fever are not met in this specific case [17, 18]. Meas-
urement of plasma procalcitonin is an alternative method 
of differentiating sepsis from paraneoplastic fever that 
may have help direct this patients management. Procal-
citonin, a pre-cursor of the hormone calcitonin, is found 
in significantly higher levels in patients with sepsis com-
pared to febrile patients with no documented evidence of 
infection [18]. This investigation is however not widely 
available and the merits of use are still debated. Lymph 
node biopsy at the time of presentation may also have 
help determine if another cause of lymphadenopathy, 
other than tumour metastasis, was responsible for the 
patients clinical picture.
A second remarkable characteristic of this case was 
the dramatic effects of surgical excision and subsequent 
chemotherapy on suppression of the systemic inflam-
matory response, albeit only temporary. Furthermore, 
the transient nature of the response to surgical excision 
only served to emphasise the extremely aggressive nature 
of the underlying disease process. Consensus guidelines 
for the management of IBC published by Dawood et al. 
and the National Comprehensive Cancer Network, rec-
ommend primary systemic chemotherapy as the first line 
treatment with aim of down-staging the disease allowing 
the possibility for definitive surgery [1, 19]. In this spe-
cific case, however, due to the profound clinical deterio-
ration and in the absence of a confirmed source of sepsis 
a multidisciplinary team decision was taken to excise 
the tumour mass for fear that the patient may not sur-
vive without surgical resection. Ultimately the observed 
SIRS response was only transiently suppressed by surgi-
cal resection and cycles of systemic chemotherapy.
The presence of a prior diagnosis of sarcoidosis, an 
immunologically mediated disease, may have contrib-
uted to the observed systemic inflammatory response. 
Whilst the pathophysiology of sarcoidosis is itself incom-
pletely understood, it is recognised that a low activation 
threshold and dysregulation of the immune system are 
important for its development and progression [20]. A 
systematic review of the literature reveals no previous 
published reports of IBC in the presence of sarcoidosis. 
Notwithstanding, it may be hypothesised that in the con-
text of existing immune dysfunction, the local and sys-
temic inflammatory effects of IBC can be significantly 
augmented.
Conclusion
This case report represents the first description of a 
potential paraneoplastic systemic inflammatory response 
in the context of inflammatory breast cancer. This report 
contributes to the existing published literature that seeks 
to characterise and define the underlying link between 
the inflammatory process and IBC. It also serves as a 
reminder of the aggressive and unpredictable nature of 
this disease and offers new insight into the challenges 
faced by clinicians charged with its management.
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